SKIN Stock Forecast & Price Target

SkinHealth Systems is positioned for upside because its recurring-consumables model remains durable, with about 75% of revenue from consumables and an active installed base of 36,516 systems up ~4% y/y, supporting long-term monetization even as device sales soften. Although 2Q26 revenue fell 8% y/y to $72.1M on Delivery Systems weakness, adjusted EBITDA rose to $17.0M and beat guidance by a wide margin, helped by gross margin expansion to 71.8%, lower inventory-related charges, and disciplined expense control. The outlook is further strengthened by the new U.S. rental program, HydraScalp traction, nearly 50% y/y SkinStylus growth in 2Q, and a clinically validated booster launch expected in 4Q26, which together broaden growth drivers and improve utilization.

SkinHealth Systems is viewed negatively because its market cap of about $91M sits below its roughly $206M cash balance, yet the business still faces weak visibility into durable free cash flow and a $250MM November 2028 convertible maturity that hangs over the balance sheet. FY26 revenue guidance was reduced, 3Q26 revenue is guided to $65-70MM with adj. EBITDA of $5-7MM, and both device demand and consumables utilization remain pressured, signaling that the expected turnaround is still fragile. The fundamentals are further weakened by Delivery Systems revenue down 18% y/y, only 97 net active install-base additions from 770 placements, and ongoing litigation and regulatory risks that could continue to suppress cash generation and brand strength.